Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: bio_kruncher who wrote (11079)	3/31/2004 9:33:17 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Thanks bio_kruncher. So either they didn't know what they were doing or tried to do a big spin. That fits with their past behavior. I recall particularly an earlier Rubitecan trial in which they trumpeted the response rate in "evaluable" patients where their definition of "evaluable" was that the patients had completed at least two courses of treatment. So the patients that dropped out or died during the first course (which was something like 4 weeks of treatment) were not considered evaluable. (I may have the details wrong because this was a few years ago and I'm speaking from memory). Nevertheless I believe that Dacogen is a very interesting drug. Also seems to be an intriguing treatment (at low doses) for sickle cell patients. Peter